Bifogade filer
PDF
Kurs
-3,36%
Likviditet
7,99 MSEK
Kalender
| Est. tid* | ||
| 2025-11-04 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-19 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-12 | N/A | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2025-06-11 | N/A | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-04 | - | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-06 | - | Bokslutskommuniké 2023 |
| 2023-11-21 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-16 | - | Extra Bolagsstämma 2023 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-01 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2023-05-31 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2022-06-02 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2021-05-19 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-09 | - | Extra Bolagsstämma 2021 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-19 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning OSSD 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release.
"Despite operating in a highly competitive market, we have shown there are vast growth opportunities when offering state-of-the-art innovation that solves the clinical challenges" said Morten Henneveld, CEO, OssDsign AB.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser
The Company's Certified Adviser is DNB Carnegie Investment Bank AB
About OssDsign
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
This disclosure contains information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 07:00 CET on May 14th, 2025.